Customer and contract value undisclosed

Lotte Biologics has secured its first large-scale commercial production order ahead of the completion ceremony for its plant in Songdo, Incheon. It is seen as having laid the groundwork for generating revenue as soon as the plant begins operations.

A view of Plant 1 at Lotte Biologics' Songdo Bio Campus in Yeonsu-gu, Incheon. Lotte Biologics

A view of Plant 1 at Lotte Biologics' Songdo Bio Campus in Yeonsu-gu, Incheon. Lotte Biologics

View original image

On November 17, Lotte Biologics announced that it had signed a contract with a global pharmaceutical company to manufacture biopharmaceuticals under a contract manufacturing organization (CMO) agreement. This is the first large-scale commercial production order for Plant 1 at its Songdo Bio Campus. Under the terms of the contract, the customer and the contract value were not disclosed. Lotte Biologics plans to provide a "one-stop service," handling the entire production process for the customer's key products, from active pharmaceutical ingredients to finished drug products.


The contract gives Lotte Biologics production volume in advance to support the initial operation of its Songdo Plant 1 after completion. Unlike the usual practice of seeking major orders after a plant is fully built, the company is seen as having proactively laid the groundwork by attracting customers during the design and construction stages.


Songdo Plant 1 is a production facility with a total capacity of 120,000 liters, equipped with eight 15,000-liter stainless steel bioreactors. The company aims to begin full-scale commercial production next year.


Lotte Biologics is expanding its global supply network through a "dual-site" strategy that combines commercial production experience at its Syracuse Bio Campus in the United States with Songdo's large-scale production capacity. The Syracuse campus has secured more than 62 regulatory agency approvals and recently recorded zero observations in an inspection by the U.S. Food and Drug Administration (FDA). The company plans to apply this quality management expertise at its Songdo campus as well.



James Park, CEO of Lotte Biologics, said, "This contract demonstrates that Lotte Biologics is establishing itself as a key supply chain partner for global customers, rather than simply being a new entrant in the CDMO market. We will actively support our customers' successful commercialization of new drugs, drawing on our accumulated quality competitiveness and reliable supply capabilities."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing